PDPL

Parenteral Drugs (India) Limited has informed the Exchange that there is a change in the company's directorate due to appointment of Mr. Balkrishna V. Chaubal as Nominee Director on the Board of the Company w.e.f October 14, 201 5 pursuant to intimation of appointment received by the Company on October 14, 2015.

Parenteral Drugs (India) Limited has informed the Exchange that the company has commenced its production at the relocated Plant situated at Village Panwa, Tehsil Kasrawad, District Khargone, Madhya Pradesh on October 07, 2015.

Parenteral Drugs (India) Limited has informed the Exchange that A meeting of the Board of Directors of the company was held on September 30, 2015 at the Corporate Office of the Company at Indore. The Board inter-alia considered and approved the allotment of 0% Non-cumulative, Non-convertible, Redeemable Preference Shares of the Company.

Parenteral Drugs (India) Limited has informed the Exchange that the "Trading Window'' of the Company shall remain closed from September 22, 2015 to October 2, 2015 and will open on October 3, 2015 for insiders accordingly

Parenteral Drugs (India) Limited has submitted to the Exchange a copy of Scrutinizer's Report on Postal Ballot conducted by the company in accordance with the provisions of Section 110 of Companies Act, 20 13 read with Rule 22 of the Companies (Management and Administration) Rules, 2014.

Parenteral Drugs (India) Limited has submitted to the Exchange the details of voting results of the Annual General Meeting of the Company held on the August 31, 2015 along with Report of Scrutinizer pursuant to clause 35A of the Listing Agreement.

Parenteral Drugs (India) Limited has informed the Exchange regarding the Outcome of the Annual General Meeting of the Members of the Company held on August 31, 2015.

Parenteral Drugs (India) Limited has informed the Exchange regarding the discontinuation of manufacturing operations due to relocation of plant.

Parenteral Drugs (India) Limited has informed the Exchange that the company has initiated the process of relocation of the plant situated at Village Asrawad, Post Dudhia, Nemawar Road, Indore, Madhya Pradesh to Village Panwa, Tehsil Kasrawad, District Khargone, Madhya Pradesh in April 2015 and for the purpose of relocation of the same, since, the civil work has almost been completed for its IV Fluids and allied manufacturing activities, the company has discontinued its manufacturing operations at Village Asrawad w.e.f. August 24, 2015. The company will inform the commencement of manufacturing

Parenteral Drugs (India) Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from August 25, 2015 to August 31, 2015 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on August 31, 2015 .

Parenteral Drugs (India) Limited has informed the Exchange regarding Outcome of Board Meeting held on July 18, 2015.

Parenteral Drugs (India) Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 30-Jun-2015.

Parenteral Drugs (India) Limited has informed the Exchange that there is a change in the company's directorate in terms of Clause 30(a) of the Listing Agreement due to death of Shri S.C. Consul, Independent Director of the Company on July 14, 2015.

Parenteral Drugs (India) Limited has informed the Exchange that in respect of Company s Code of Conduct to regulate, monitor and report trading by insiders for Prevention of Insider Trading in the Equity shares and for the aforesaid purpose the "Trading Window" of the Company shall remain closed from the date of intimation i.e. July 09, 2015 to July 20, 2015 and will open on July 21, 2015 for insiders accordingly

Parenteral Drugs (India) Limited has informed the Exchange regarding the Code of Practices, procedure and code of conduct to regulate, monitor and report trading in securities and fair disclosure of unpublished price sensitive information pursuant to the requirements of the securities and exchange board of india (prohibition of insider trading) Regulations, 2015.

Parenteral Drugs (India) Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 30, 2015, approved the Code of Conduct of the company for the Board of Directors and the Designated persons of the company. The Company made provisions for writing off the amount invested in two foreign subsidiaries viz. Mascareignes Pharmaceuticals Manufacturing Limited, Mauritius and Parenteral Drugs Kazakhstan, Kazakhstan.

Parenteral Drugs (India) Limited has submitted to the exchange the standalone & consolidated financial results along with the Auditors Report for the period ended 31-Mar-2015.

Parenteral Drugs (India) Limited has informed the Exchange that the "Trading Window" of the Company shall remain closed from May 29, 2015 to June 1, 2015 and will open on June 2, 2015 for insiders accordingly.

Rajratan Exports Private Limited has submitted to the Exchange vide letter dated April 07, 2015 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parenteral Drugs (India) Limited has informed the Exchange that the meeting of the Board of Directors of the Company held on March 30, 2015 considered & approved inter-alia appointment of Ms. Deepali Garhewal as an additional and Independent director on the Board of the Company and relocation of the Indore plant of the Company situated at Village Asrawad, Post Dhudhia, Nemawar Road, Indore (Madhya Pradesh) to Village Panwa, Tehsil Kasrawad, District Khargone, Madhya Pradesh.

Parenteral Drugs (India) Limited has informed the Exchange that as per Regulation 12 of the SEBI (Prohibition of Insider Trading) Regulations, 1992, in respect of Company's Code of Conduct for Prevention of Insider Trading in the Equity shares, it is hereby informed that for the purpose Board Meeting "Trading Window" of the Company shall remain closed from March 28, 2015 to March 31, 2015 and will open on April 1, 2015 for insiders accordingly.

SBICAP Trustee Company Ltd has submitted to the Exchange, vide letter dated February 11, 2015 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parenteral Drugs (India) Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 31-Dec-2014.

SBICAP Trustee Company Ltd has submitted to the Exchange, vide letter dated February 09, 2015 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parenteral Drugs (India) Limited has informed the Exchange that a meeting of the Board of Directors of the Company will be held on Tuesday, the February 10, 2015 at 11.30 a.m. and for this purpose "Trading Window" of the Company shall remain closed from February 09, 2015 to February 11, 2015 and will open on February 12, 2015 for insiders accordingly.

SBICAP Trustee Company Limited has submitted to the Exchange, vide letter dated January 21, 2015 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parenteral Drugs (India) Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 30-Sep-2014.

Parenteral Drugs (India) Limited has informed the Exchange that M/s Punjab Formulations Limited, a wholly owned subsidiary company has merged with Goa Formulations Limited, a wholly owned subsidiary company, pursuant to the order issued by the Hon ble High Court of Judicature at Bombay and Scheme of Amalgamation sanctioned thereon by the Hon ble High Court dated September 12, 2014. Further, name of Goa Formulations Limited has been changed from Goa Formulations Limited to Infutec Healthcare Limited w.e.f. October 31, 2014.

Parenteral Drugs (India) Limited has informed the Exchange that as per Regulation 12 of the SEBI (Prohibition of Insider Trading) Regulations, 1992, in respect of Company's Code of Conduct for Prevention of Insider Trading in the Equity shares, it is hereby informed that a meeting of the Board of Directors of the Company will be held on November 14, 2014 and for this purpose "Trading Window" of the Company shall remain closed from November 12, 2014 to November 16, 2014 and will open on November 17, 2014 for insiders accordingly.

Parenteral Drugs (India) Limited has submitted to the Exchange a copy pertaining details of voting results pursuant to clause 35A of the Listing Agreement.

Parenteral Drugs (India) Limited has informed the Exchange regarding a Outcome of Annual General Meeting of the Company held on September 30, 2014.

Parenteral Drugs (India) Limited has submitted to the Exchange a copy of Notice of the Annual General Meeting to be held on September 30, 2014.

Parenteral Drugs (India) Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from September 23, 2014 to September 30, 2014 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on September 30, 2014.

Parenteral Drugs (India) Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 30-Jun-2014.

Parenteral Drugs (India) Limited has informed the Exchange that as per Regulation 12 of the SEBI (Prohibition of Insider Trading) Regulations, 1992, in respect of Company's Code of Conduct for Prevention of Insider Trading in the Equity shares, it is hereby informed that a meeting of the Board of Directors of the Company will be held on August 14, 2014 and for this purpose "Trading Window" of the Company shall remain closed from 12th August, 2014 to 15th August, 2014 and will open on 16th August, 2014 for insiders accordingly.

Parenteral Drugs (India) Limited has informed the Exchange that Mr. Satish Moreshwar Joshi, nominee director of the company has tendered his resignation from directorship of the company w.e.f. June 30, 2014 due to his personal priorities.

Parenteral Drugs (India) Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Mar-2014.

Parenteral Drugs (India) Limited has informed the Exchange that in respect to frame Company's Code of Conduct for Prevention of Insider Trading in the Equity shares, it is hereby informed that a meeting of the Board of Directors of the Company will be held on Friday, the 30th day of May, 2014 at 11.00 a.m. For this purpose "Trading Window" of the Company shall remain closed from 29th May, 2014 to 2nd June, 2014 and will open on 3rd June, 2014 for insiders accordingly.

Parenteral Drugs (India) Limited has informed the Exchange that Ms. Aradhana Kulkarni has been appointed as Company Secretary and Compliance Officer of the Company w.e.f. April 18, 2014 by the management of the Company.

Parenteral Drugs (India) Limited has informed the Exchange that the production at the newly established plant of Punjab Formulations Limited, a subsidiary of the Company, situated at Village Ahirana, Dist. Hoshiarpur, Punjab has started and the production activity of previous plant situated at Village Sura (P.O.) Suranussi, Jalandar, Punjab has been discontinued.

Parenteral Drugs (India) Limited has informed the Exchange that the proposed resignation of Mr.Yogesh Khakre from the post of Company Secretary and Compliance Officer of the Company w.e.f. March 01, 2014 has been approved by the management of the Company on March 18, 2014. Consequently he has ceased to be the Company Secretary and Compliance Officer of the Company w.e.f. March 01, 2014.

Price movement : Significant price movement has been observed in Parenteral Drugs (India) Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Parenteral Drugs (India) Limited has vide its letter inter-alia stated,"The present situation in the prices of the shares of the Company is due to the market forces and not because of the reason known to the management of the Company, as the Promoters of the Company are not trading in th

Parenteral Drugs (India) Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-dec-2013.

Parenteral Drugs (India) Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 30-sep-2013.

Parenteral Drugs (India) Limited has informed the Exchange that the Company received from M/s. Mahaganpati Investment Private Limited, Rs. 9,98,32,668/- towards the outstanding call money (including premium) on 18,26,898 partly paid-up 0% redeemable preference shares out of which Rs. 8.90 is paid towards face value and Rs. 45.746 towards premium; the shares will now be treated as fully-paid up.

Parenteral Drugs (India) Limited has informed the Exchange that Board of Directors of the Company at its meeting held on October 30, 2013 has issued and allotted 39,49,469 Fully Paid-up Equity Shares to M/s. MVG Mercantile Private Limited, a Company under promoter category, pursuant to conversion of 29,62,102, 0% Optionally Convertible Redeemable Preference Shares.

Parenteral Drugs (India) Limited has informed the Exchange regarding the outcome of the Annual General Meeting of the Company held on September 30, 2013.

Parenteral Drugs (India) Limited has informed the Exchange that "Shri Satish Moreshwar Joshi, the Nominee of State Bank of India be and is hereby appointed as a Nominee Director of the Company w.e.f. 16.08.2013 in terms of letter of approval by CDR-EG."

Parenteral Drugs (India) Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from September 27, 2013 to September 30, 2013(both days inclusive) for the purpose of Annual General Meeting.

Parenteral Drugs (India) Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended June 30,2013.